Publications by authors named "Kevin Bigaut"

Claim this Profile
E
Evolution of high-efficacy treatment strategy for relapsing-remitting multiple sclerosis: A real-life observational study.
Judicaelle Didierjean, Laurent Kremer, Livia Lanotte, Sylvie Courtois, Germain Carré, Kévin Bigaut

Mult Scler Relat Disord· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An update on the evaluation of treatment switching criteria in multiple sclerosis.
Kevin Bigaut, Judicaelle Didierjean, Jerome de Seze

Expert Rev Neurother· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing medical training with augmented reality and haptic feedback simulator: outcomes of a randomized controlled trial on lumbar puncture.
Renaud Felten, Kevin Bigaut, Thomas Wirth, Laurent Kremer, Lucas Gauer

BMC Med Educ· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System: A Multicentric Cohort Study.
Elodie Berthet, Antoine Guillonnet, Caroline Houillier, Renata Ursu, Carole Soussain, Kevin Bigaut

Ann Neurol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European experience of cladribine tablets in elderly patients with multiple sclerosis: Could it be the last treatment?
Jérôme de Seze, Chiara Zecca, Giovanni Castelnovo, Xavier Ayrignac, Patrick Vermersch, Kévin Bigaut

Mult Scler J Exp Transl Clin· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis.
Antoine Gavoille, Fabien Rollot, Romain Casey, Anne Kerbrat, Emmanuelle Le Page, Kevin Bigaut

JAMA Neurol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.
Nicolas Collongues, Françoise Durand-Dubief, Christine Lebrun-Frenay, Bertrand Audoin, Xavier Ayrignac, Kévin Bigaut

Mult Scler· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
Guillaume Jouvenot, Guilhem Courbon, Mathilde Lefort, Fabien Rollot, Romain Casey, Kevin Bigaut

JAMA Neurol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of dalfampridine in neuromyelitis optica spectrum disorder: A pilot study.
Jérôme de Seze, Christine Clerc, Matthieu Béreau, Bertrand Bourre, Hélène Zephir, Kevin Bigaut

Mult Scler J Exp Transl Clin· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study.
Augustin Moreau, Ioanna Kolitsi, Laurent Kremer, Marie Fleury, Livia Lanotte, Kévin Bigaut

Mult Scler Relat Disord· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical features and maternal and fetal outcomes in women with Guillain-Barré syndrome in pregnancy.
Nolwenn Krief, René Gabriel, Cécile Cauquil, David Adams, Guillaume Fargeot, Kevin Bigaut

J Neurol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort.
Juliette Pelle, Anais R Briant, Pierre Branger, Nathalie Derache, Charlotte Arnaud, Kevin Bigaut

Neurol Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society.
Sandra Vukusic, Clarisse Carra-Dalliere, Jonathan Ciron, Elisabeth Maillart, Laure Michel, Kevin Bigaut

Mult Scler· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society.
Sandra Vukusic, Romain Marignier, Jonathan Ciron, Bertrand Bourre, Mikael Cohen, Kevin Bigaut

Mult Scler· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study.
Michael Levraut, Sabine Laurent-Chabalier, Xavier Ayrignac, Kévin Bigaut, Manon Rival

Neurol Neuroimmunol Neuroinflamm· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients.
Maximilian Einsiedler, Laurent Kremer, Marie Fleury, Nicolas Collongues, Jérôme De Sèze, Kévin Bigaut

J Neurol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Translatability of Multiple Sclerosis Animal Models for Biomarkers Discovery and Their Clinical Use.
Dafni Birmpili, Imane Charmarke Askar, Kévin Bigaut, Dominique Bagnard

Int J Mol Sci· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
Kévin Bigaut, Laurent Kremer, Thibaut Fabacher, Guido Ahle, Mathilde Goudot

J Neurol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Good therapeutic response to infliximab in a case of Susac syndrome refractory to immunotherapies including tocilizumab.
Stanislas Demuth, Thomas Bogdan, Laurent Kremer, Livia Lanotte, Nicolas Collongues, Kévin Bigaut

J Neurol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis.
Bhagteshwar Singh, Suzannah Lant, Sofia Cividini, Jonathan W S Cattrall, Lynsey C Goodwin, Kévin Bigaut

PLoS One· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A rise in cases of nitrous oxide abuse: neurological complications and biological findings.
Maximilian Einsiedler, Paul Voulleminot, Stanislas Demuth, Pauline Kalaaji, Thomas Bogdan, Kévin Bigaut

J Neurol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases.
Lucie Isoline Pisella, Sara Fernandes, Guilhem Solé, Tanya Stojkovic, Céline Tard, Kévin Bigaut

Orphanet J Rare Dis· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study.
Kévin Bigaut, Laurent Kremer, Thibaut Fabacher, Livia Lanotte, Marie-Celine Fleury

Neurol Neuroimmunol Neuroinflamm· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP).
Kévin Bigaut, Mikaël Cohen, Françoise Durand-Dubief, Elisabeth Maillart, Evelyne Planque

Mult Scler Relat Disord· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple sclerosis diagnostic criteria: From poser to the 2017 revised McDonald criteria.
Jérôme de Seze, Kévin Bigaut

Presse Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis